Market Analysis by covering: Gold Spot US Dollar, Pfizer Inc, US Dollar Index Futures, S&P 500 Futures. Read 's Market Analysis on Investing.com ...

Core Insights - Pfizer's stock has experienced a decline of 9.90% over the past month, following a gain of 10.02% the previous month, resulting in a year-to-date loss of 7.33% and an annual decline of 11.17% [3] - The recent drop in stock price is attributed to the FDA's recommendation limiting COVID-19 vaccines to seniors and certain medical conditions, which poses a challenge for Pfizer's COVID-related revenue [4] - Pfizer's total revenues for FY 2025 are forecasted to be between $61 billion and $64 billion, with oncology sales expected to grow significantly [5] Financial Performance - Pfizer's revenue from COVID products, including Paxlovid and Comirnaty, was $11.1 billion in 2024, but the company is now focusing on non-COVID products to stabilize revenue [4][10] - The company reported a significant drop in stock price, down 20.85% over the past five years and more than 54% since its all-time high in December 2021 [6] - Pfizer's revenue and net income figures from 2015 to 2024 show fluctuations, with a peak revenue of $100.33 billion in 2022 and a net income of $31.37 billion [9] Market Outlook - Analysts project a one-year price target for Pfizer at $28.60, indicating a potential upside of 15.97% from the current share price, with a longer-term forecast of $33.60 by the end of 2025 [12] - The oncology drug market is expected to grow at an 8.1% CAGR from 2025 to 2030, which could benefit Pfizer as it reallocates resources towards this segment [10] - The obesity drug market is forecasted to expand at a 22.3% CAGR from 2025 to 2030, with Pfizer developing a new oral formulation to compete in this space [10] Strategic Partnerships - Pfizer's collaboration with Bristol Myers Squibb on the blood thinner Eliquis generated $1.83 billion in Q4 2024, marking a 14% year-over-year increase [11] - The anticoagulant market, valued at $34.8 billion in 2023, is projected to grow at a 10.2% CAGR from 2024 to 2030, presenting further opportunities for Pfizer [11]

Core Viewpoint - Pfizer reported a decline in third-quarter profit due to decreasing demand for its Covid-19 vaccine and antiviral drug [1] Financial Performance - The company experienced lower profits in the third quarter compared to previous periods, indicating a significant impact from reduced sales of Covid-19 related products [1] Market Demand - There is a continuing decline in demand for both the Covid-19 vaccine and antiviral treatments, which has been a major revenue source for Pfizer [1]

Financial Performance - Third-quarter 2025 revenues totaled $16.7 billion, a decrease of 6% year-over-year, reflecting an operational decline of 7%[4] - Reported diluted EPS for the third quarter was $0.62, down 21% from the prior year, while adjusted diluted EPS was $0.87, also down 18%[4] - Product revenues for Q3 2025 were $13.92 billion, a decrease of 10% compared to $15.42 billion in Q3 2024[34] - Total revenues for the first nine months of 2025 were $45.02 billion, down 2% from $45.86 billion in the same period of 2024[34] - Net income attributable to Pfizer Inc. common shareholders for Q3 2025 was $3.54 billion, a decrease of 21% from $4.47 billion in Q3 2024[34] - Total revenues for 2025 were $16,654 million, a decrease of 6% compared to $17,702 million in 2024[53] - The Global Biopharmaceuticals business generated $16,310 million in 2025, down 6% from $17,392 million in 2024[53] - Total revenues for 2025 were $45,022 million, a decrease of 2% compared to $45,864 million in 2024[55] - The Global Biopharmaceuticals business generated $44,056 million in 2025, down 2% from $44,987 million in 2024[55] Guidance and Projections - The company reaffirms full-year 2025 revenue guidance in the range of $61.0 to $64.0 billion[4] - Adjusted diluted EPS guidance for 2025 has been raised and narrowed to a range of $3.00 to $3.15, up from the previous range of $2.90 to $3.10[9] - Pfizer expects an unfavorable revenue impact of approximately $0.4 billion due to generic and biosimilar competition for certain products[31] - The company is on track to deliver approximately $7.7 billion in anticipated overall savings from cost improvement initiatives[32] - Pfizer's ongoing cost realignment program is expected to achieve approximately $4.5 billion in net cost savings by the end of 2025[32] Research and Development - The company invested approximately $7.2 billion in internal R&D projects and $1.6 billion in business development transactions during the first nine months of 2025[11] - Pfizer's development pipeline includes a comprehensive update available on their website, detailing compounds in various phases of development[25] - In the Phase 2 PHAROS trial, Braftovi + Mektovi showed a median overall survival of 47.6 months for treatment-naïve patients after a median follow-up of 52.3 months[20] - The Phase 3 clinical trial of the LP.8.1-adapted Comirnaty COVID-19 vaccine demonstrated a robust increase in neutralizing antibodies in adults aged 65 and older[22] - The Phase 3 EV-303 trial for Padcev showed a 60% reduction in the risk of tumor recurrence or death compared to surgery alone, with an estimated 74.7% event-free rate at two years[23] - Xtandi plus leuprolide reduced the risk of death by 40.3% in men with non-metastatic hormone-sensitive prostate cancer, with an 8-year overall survival of 78.9%[24] - Inclacumab did not meet its primary endpoint in the Phase 3 THRIVE-131 study for sickle cell disease, although it was generally well tolerated[26] Acquisitions and Strategic Initiatives - Pfizer secured early FTC clearance for the proposed Metsera acquisition, aimed at enhancing competition in the obesity market[3] - Pfizer has entered into a definitive agreement to acquire Metsera for $4.9 billion, with potential additional payments of up to $22.50 per share tied to specific milestones[27] - The U.S. Federal Trade Commission granted early termination of the waiting period for Pfizer's acquisition of Metsera, obtaining all required regulatory approvals[27] - The company is confident in the merits of its lawsuits against Metsera and Novo Nordisk regarding a competing acquisition proposal[27] Cost Management and Expenses - Pfizer is on track to deliver approximately $7.2 billion in anticipated net cost savings from previously announced cost improvement initiatives by the end of 2027[4] - Adjusted cost of sales for Q3 2025 was $3,979 million, an 18% decrease from $4,874 million in Q3 2024, representing 23.9% of revenues[19] - Adjusted R&D expenses for the first nine months of 2025 were $7,096 million, down 8% from $7,708 million in the same period of 2024[19] - Restructuring charges for the third quarter of 2025 totaled $286 million, compared to $313 million in the same period of 2024, with total charges for the first nine months of 2025 amounting to $945 million, down from $1.669 billion in 2024[37] - Net interest expense decreased to $514 million in the third quarter of 2025 from $668 million in 2024, with total interest expense for the first nine months of 2025 at $1.523 billion, down from $1.977 billion in 2024[38] Market Challenges and Risks - The company is facing risks related to the proposed acquisition of Metsera, including competition from Novo Nordisk's proposal and uncertainties in closing the transaction[62] - The company reported challenges in marketing existing products and potential delays in manufacturing and sales due to supply chain disruptions[62] - The impact of COVID-19 on the company's financial condition remains uncertain, with potential reduced demand for COVID-19 products leading to decreased revenues[62] - The company is navigating risks associated with tariffs, geopolitical instability, and climate change disruptions that could affect operations[64] - The company is evaluating its product portfolio for potential risks related to nitrosamines, which may impact product recalls and regulatory assessments[64] - The company is facing uncertainties regarding the approval and commercialization of new product candidates, which may require additional clinical data[67] - The company is exposed to risks related to intellectual property, including potential patent challenges and cybersecurity threats[69] Taxation and Financial Metrics - Pfizer's effective tax rate on reported income for Q3 2025 decreased to 7.9% from 10.8% in Q3 2024, primarily due to favorable changes in earnings jurisdiction and tax benefits[19] - The effective tax rates for income from continuing operations were (6.5)% for the third quarter of 2025, compared to 5.0% in 2024, primarily due to a favorable change in the jurisdictional mix of earnings[41] - Adjusted income is used by management to evaluate overall performance, excluding certain items such as amortization of intangible assets and acquisition-related costs[43] - The company aims to enhance investor understanding of performance through the disclosure of adjusted income and adjusted diluted EPS as non-GAAP financial measures[43] Shareholder Returns - Total shareholder return is a significant factor in determining payouts under the company's incentive compensation plans[44] - Non-GAAP adjusted net income for Third-Quarter 2025 was $4,949 million, resulting in diluted earnings per share of $0.87[46] - For the nine months ended September 28, 2025, GAAP reported net income was $2,210 million, with diluted earnings per share of $1.65[46] - Non-GAAP adjusted net income for the nine months ended September 28, 2025 was $14,620 million, leading to diluted earnings per share of $2.56[46]

Core Insights - Pfizer reported third-quarter earnings and revenue that exceeded estimates, raising its full-year profit guidance due to cost-cutting measures offsetting declining sales [1] - The company became the first drugmaker to agree to sell medications at lower prices under a deal with President Trump, linking U.S. drug prices to those abroad [1] - Pfizer plans to invest $70 billion in U.S. manufacturing and research facilities as part of a three-year grace period to avoid pharmaceutical-specific tariffs [2] Financial Performance - Adjusted earnings per share were reported at 87 cents, surpassing the expected 63 cents [4] - Revenue for the quarter was $16.65 billion, slightly above the expected $16.58 billion [4] Competitive Landscape - Pfizer is engaged in a bidding war with Novo Nordisk for the acquisition of obesity biotech Metsera, filing a lawsuit against Novo Nordisk for alleged anticompetitive practices [3]

Core Insights - Pfizer raised its full-year profit forecast for the second consecutive time, driven by robust demand for its leading heart treatment and blood thinner [1] Company Summary - Pfizer's updated profit forecast reflects strong market performance and increased sales of its key pharmaceutical products [1]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Pfizer reported solid third-quarter 2025 results, reaffirming its revenue guidance while raising and narrowing its adjusted diluted EPS guidance for the year [1][7][12] Financial Performance - Third-quarter 2025 revenues totaled $16.7 billion, a decrease of 6% year-over-year, with an operational decline of 7% [5][15] - Reported net income for the third quarter was $3.54 billion, down 21% from $4.47 billion in the prior year [5] - Reported diluted EPS was $0.62, a decrease of 21% compared to $0.78 in the same quarter last year [5] - Adjusted diluted EPS for the third quarter was $0.87, down 18% from $1.06 in the prior year [8] Revenue Breakdown - The biopharmaceutical segment generated $16.31 billion in revenues, a 6% decline year-over-year [9] - Significant declines were noted in COVID-19 product revenues, particularly Paxlovid and Comirnaty, due to lower infection rates and a narrower vaccination recommendation [17][15] - Non-COVID portfolio showed a 4% operational revenue growth, indicating strengthened commercial execution [7] Guidance and Cost Management - Pfizer reaffirmed its full-year 2025 revenue guidance in the range of $61.0 to $64.0 billion [11] - Adjusted diluted EPS guidance was raised to a range of $3.00 to $3.15, reflecting confidence in business performance and cost improvement initiatives [12][11] - The company is on track to deliver approximately $7.2 billion in net cost savings from previously announced cost improvement initiatives by the end of 2027 [7][42] Strategic Developments - Pfizer reached a landmark agreement with the U.S. Government to ensure drug pricing parity with other developed countries, enhancing business clarity [2][31] - The company secured early FTC clearance for the proposed acquisition of Metsera, aimed at competing in the obesity market [6][32] - Pfizer is involved in legal actions against Metsera and Novo Nordisk regarding a competing acquisition proposal, seeking to enforce the merger agreement [33][35] Recent Product Developments - Positive results were announced for several ongoing clinical trials, including the Phase 3 trial for Comirnaty and the Phase 2 trial for Braftovi + Mektovi [25][28] - The company continues to invest in its pipeline, with a comprehensive update available on its website [28]

Pfizer Inc. (NYSE:PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4.Analysts expect the health care company to report quarterly earnings at 64 cents per share, down from $1.06 per share in the year-ago period. The consensus estimate for Pfizer’s quarterly revenue is $16.52 billion, down from $17.7 billion a year earlier, according to Benzinga Pro.On Friday, Pfizer filed a lawsuit against Metsera, Inc. (NASDAQ:MTSR), its Board of Directors, and Novo Nordisk ( ...

Earnings Report - Pfizer Inc. is set to release its third-quarter earnings results on November 4, with analysts expecting earnings of 64 cents per share, a decrease from $1.06 per share in the same period last year [1] - The consensus estimate for Pfizer's quarterly revenue is $16.52 billion, down from $17.7 billion a year earlier [1] Legal Action - Pfizer has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk in a Delaware Court, claiming breach of contract, breach of fiduciary duty, and tortious interference due to Metsera's failure to meet obligations under a merger agreement with Pfizer [2] - Following the lawsuit, Pfizer's shares rose by 0.04% to close at $24.66 [2] Analyst Ratings - Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and reduced the price target from $33 to $32 [5] - B of A Securities analyst Tim Anderson maintained a Neutral rating and raised the price target from $28 to $30 [5] - Citigroup analyst Andrew Baum maintained a Neutral rating and increased the price target from $25 to $26 [5] - UBS analyst Trung Huynh maintained a Neutral rating and raised the price target from $24 to $25 [5] - Cantor Fitzgerald analyst Carter Gould initiated coverage with a Neutral rating and a price target of $24 [5]